Manual of stem cell and bone marrow transplantation

Manual of Stem Cell and Bone Marrow Transplantation

Volumn , Issue , 2009, Pages 1-177

  Antin, Joseph H ^a   Raley, Deborah Yolin ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926222678     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511575785     Document Type: Book

References (24)

1. Armand P, Antin JH. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2007 May; 13 (5): 505–516.
2. Benjamin RJ, Antin JH. ABO-incompatible bone marrow transplantation: Th e transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion. 1999 Nov–Dec; 39 (11–12): 1273–1274.
3. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR. 2000;49:rr-10:1–128.
4. Nevill TJ, Tirgan MH, Deeg HJ, et al. Infl uence of postmethotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992 May; 9 (5): 349–354.
5. Delgado J, Th ompson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: A British Society of Blood and Marrow Transplantation. Blood. 2006; 107:1724–1730.
6. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant. 1998; 22: 61–65.
7. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with Graft-Versus-Host Disease steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002; 8: 40–46.
8. Vogelsang GB. Advances in the treatment of graft-versus-host disease. Leukemia. 2000; 14: 509–510.
9. Lee SJ, Zahrieh D, Agura E, et al. Eff ect of up-front daclizumab when combined with steroids for the treatment of acute graftversus-host disease: Results of a randomized trial. Blood. 2004 Sep 1; 104 (5): 1559–1564. Epub 2004 May 11.
10. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus disease I. Diagnosis and staging working group report. Biol Blood marrow Transplant. 2005; 11 (12): 945–956.
11. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985 Dec; 152 (6): 1172–1181.
12. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: Incidence, risk factors and complications. Bone Marrow Transplant. 1994 Mar; 13 (3): 277–283.
13. Chien JW, Martin PJ, Gooley TA, et al. Airfl ow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003; 168: 208–214.
14. Afessa B, Litzow MR, Teff eri A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation (Review). Bone Marrow Transplant. 2001; 28: 425–434.
15. Khalid M, Al Saghir A, Saleemi S, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: A preliminary study. Eur Resp J. 2005; 25: 490–493.
16. Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defi brotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2004 May; 10 (5): 347–354.
17. Corbacioglu S, Hönig M, Lahr G, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defi - brotide. Bone Marrow Transplant. 2006 Oct; 38 (8): 547–553. Epub 2006 Sep 4.
18. Bearman SI, Lee JL, Barón AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood. 1997 Mar 1; 89 (5): 1501–1506.
19. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defi brotide: Compassionate use Veno-Occlusive Disease results in response without signifi cant toxicity in a high-risk population. Blood. 1998 Aug 1; 92 (3): 737–744.
20. Richardson PG, Murakami C, Jin Z, Warren D, et al. Multiinstitutional use of defi brotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without signifi cant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100 (13): 4337–4343. Epub 2002 Aug 1.
21. Chopra R, Eaton JD, Grassi A, Potter M, et al. Defi brotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol. 2000 Dec; 111 (4): 1122–1129.
22. Seeley WW, Marty FM, Holmes TM, et al. Post-transplant acute limbic encephalitis: an HHV6-induced neurological syndrome? Neurology. 2007; 69: 156–165.
23. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of fi rst hematological relapse afterallogeneic stem-cell transplantation in adults with acute myeloid leukemia: aretrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007 Nov 1; 25 (31): 4938–4945. Epub 2007 Oct 1.
24. Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000 Sep; 26 (5): 511–516.